Evidence map›Paper›PMID 38561470›Full record

ArticleScientific reports2024

Exploring bi-carbazole-linked triazoles as inhibitors of prolyl endo peptidase via integrated in vitro and in silico study.

Saeed Ullah, Farheen Mansoor, Salman Ali Khan, Uzma Jabeen, Amany I Almars, Hailah M Almohaimeed, Ahmed M Basri, Fahad M Alshabrmi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Saeed Ullah *Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan.
Farheen Mansoor *Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan.
Salman Ali KhanTunneling Group, Biotechnology Centre, Doctoral School, Silesian University of Technology, Akademicka 2, 44-100, Gliwice, Poland. salman.ali@polsl.pl.
Uzma JabeenDepartment of Biochemistry, Federal Urdu University of Karachi, Gulshan-e-Iqbal, Karachi, 75300, Pakistan.
Amany I AlmarsDepartment of Medial Laboratory Sciences, Faculty of Applied Medical Science, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Hailah M AlmohaimeedDepartment of Basic Science, College of Medicine, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, 11671, Riyadh, Saudi Arabia.
Ahmed M BasriDepartment of Medial Laboratory Sciences, Faculty of Applied Medical Science, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Fahad M AlshabrmiDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, 51452, Buraydah, Saudi Arabia.
King Abdulaziz University · SAUniversity of Karachi · PKInternational Center for Chemical and Biological Sciences · PKPrincess Nourah bint Abdulrahman University · SAQassim University · SASilesian University of Technology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A serine protease called prolyl endopeptidase (PEP) hydrolyses the peptide bonds on the carboxy side of the proline ring. The excessive PEP expression in brain results in neurodegenerative illnesses like dementia, Alzheimer's disease, and Parkinson's disease. Results of the prior studies on antioxidant activity, and the non-cytotoxic effect of bi-carbazole-linked triazoles, encouraged us to extend our studies towards its anti-diabetic potential. Hence, for this purpose all compounds 1-9 were evaluated to reveal their anti-prolyl endo peptidase activity. Fortunately, seven compounds resulted into significant inhibitory capability ranging from 26 to 63 µM. Among them six compounds 4-9 exhibited more potent inhibitory activity with IC

Indexed as

Peptide HydrolasesTriazolesCarbazolesMolecular Docking SimulationProlyl OligopeptidasesSerine EndopeptidasesStructure-Activity RelationshipCarbazolesPeptide HydrolasesProlyl OligopeptidasesSerine EndopeptidasesTriazolesBi-carbazole-linked triazolesIn vitroKinetic studiesMolecular docking simulationProlyl endo peptidase inhibitory activity

Identifiers

PMID38561470
PMCPMC10985113
OpenAlexW4393376114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.